Teclistamab Long-term Response RR Multiple Myeloma

by: Niels Van de Donk, MD, Amsterdam UMC

Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show promising results in patients with relapsed/refractory multiple myeloma (RRMM) based on long-term follow-up from the MajesTEC-1 study. After approximately 2 years of follow-up, patients treated with teclistamab achieved deep and durable responses, with a median progression-free survival of 12.5 months and a median duration of response of 24 months. These findings support teclistamab as a safe and effective off-the-shelf BCMA bispecific therapy for RRMM patients.